JSR (4185) Q2 2025 earnings summary

Executive summary

• Completed privatization and delisting in June, enabling agile restructuring and strategic investments in partnership with JICC.

• Revenue rose 9% year-over-year to 197.7 billion yen, driven by strong Digital Solutions business performance.

• Digital Solutions delivered strong growth and operating profit, while Life Science suffered losses from one-time events, operational issues, and weak biotech market conditions.

• Plastics business underperformed due to softness in automotive and construction sectors, with minimal revenue growth and flat core operating profit.

Financial highlights

• Semiconductor business sales expanded 40% year-over-year, driven by AI and high-compute applications; advanced photoresist sales grew 45% year-on-year.

• Consolidated revenue increased by 16.9 billion yen (+9%) year-over-year for the first half.

• Life Science business posted significant losses, mainly from impairment, quality, and operational issues at KBI, and a 26% revenue decline to 35.7 billion yen.

• Core operating profit turned negative at -17.8 billion yen, with non-core expenses including CDMO fixed asset impairment.

• Net income fell by 20.6 billion yen year-over-year, reflecting operational and special factors.

Outlook and guidance

• Positive momentum expected in Digital Solutions for the second half, especially in semiconductor materials driven by generative AI demand.

• Life Science business expects medium- to long-term growth potential, with ongoing structural reforms to improve profitability.

• Plastics sector anticipates improvement in the second half due to price revisions and asset efficiency focus.

• Aims for double-digit sales growth in semiconductor materials towards 2030, focusing on AI-related products.